Drug Profile


Alternative Names: Anti-CXCL10 antibody; Anti-IP10 antibody; BMS-936557; MDX-1100

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; Medarex
  • Class Antirheumatics; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Crohn's disease; Ulcerative colitis
  • Discontinued Multiple sclerosis; Rheumatoid arthritis; Spinal cord injuries

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Oct 2015 No recent reports of development identified - Phase-II for Ulcerative colitis in Russia, Ukraine, Poland, Romania, Mexico, Latvia, Mexico, Czech Republic, France, Netherlands, Hungary, Germany, Italy, Belgium, South Africa, Canada, Australia, Brazil, Austria, USA (IV)
  • 04 Oct 2015 No recent reports of development identified - Phase-II for Crohn's disease (Treatment-experienced) in Poland, Israel, France, Belgium, Hungary, USA, Puerto Rico and South Africa (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top